Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial
Lancet Oncol 2021 May 11;[EPub Ahead of Print], PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, BS Kahl, J Radford, M Solh, A Stathis, PL Zinzani, K Havenith, J Feingold, S He, Y Qin, D Ungar, X Zhang, C Carlo-StellaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.